Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
Yasir Y. Elamin, Jacqulyne Robichaux, Brett W. Carter, et al.
Cancer Cell (2022) Vol. 40, Iss. 7, pp. 754-767.e6
Open Access | Times Cited: 79

Showing 1-25 of 79 citing articles:

Rare molecular subtypes of lung cancer
Guilherme Harada, Soo‐Ryum Yang, Emiliano Cocco, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 4, pp. 229-249
Open Access | Times Cited: 73
IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
Sonia Patel, Monique B. Nilsson, Yan Yang, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 7, pp. 1292-1304
Open Access | Times Cited: 55
Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries
Vincent D. de Jager, Wim Timens, Arnaud Bayle, et al.
The Lancet Regional Health - Europe (2024) Vol. 38, pp. 100838-100838
Open Access | Times Cited: 24
Patient‐derived xenograft model in cancer: establishment and applications
Ao Gu, Jiatong Li, Mengyao Li, et al.
MedComm (2025) Vol. 6, Iss. 2
Open Access | Times Cited: 5
3D bioprinted vascularized lung cancer organoid models with underlying disease capable of more precise drug evaluation
Yoo‐mi Choi, Haram Lee, Minjun Ann, et al.
Biofabrication (2023) Vol. 15, Iss. 3, pp. 034104-034104
Closed Access | Times Cited: 40
Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions
Zofia Piotrowska, Daniel S.W. Tan, Egbert F. Smit, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 26, pp. 4218-4225
Open Access | Times Cited: 31
Novel therapeutic strategies for rare mutations in non-small cell lung cancer
Qitao Gou, Qiheng Gou, Xiaochuan Gan, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 13
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
Fei Zhou, Haoyue Guo, Yang Xia, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 10
Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical Need
G. Pretelli, Calogera Claudia Spagnolo, Giuliana Ciappina, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8878-8878
Open Access | Times Cited: 20
EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates
Daniel Sentana‐Lledo, Emmeline C. Academia, Hollis Viray, et al.
Translational Lung Cancer Research (2023) Vol. 12, Iss. 7, pp. 1590-1610
Open Access | Times Cited: 20
Non-small cell lung cancer: an update on emerging EGFR-targeted therapies
Valentina Favorito, Ilaria Ricciotti, Andrea De Giglio, et al.
Expert Opinion on Emerging Drugs (2024) Vol. 29, Iss. 2, pp. 139-154
Closed Access | Times Cited: 6
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Xiaojuan Yang, Hong Wu
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 6
Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations
Jia Li Low, Sun Min Lim, Jii Bum Lee, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 16
EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies
Qianming Bai, Jialei Wang, Xiaoyan Zhou
Cancer Treatment Reviews (2023) Vol. 120, pp. 102605-102605
Open Access | Times Cited: 15
Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: Results from LC-SCRUM-Asia
Masanobu Okahisa, Hibiki Udagawa, Shingo Matsumoto, et al.
Lung Cancer (2024) Vol. 191, pp. 107798-107798
Closed Access | Times Cited: 5
A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations
Huanlan Sa, Yan Shi, Chunxia Ding, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 10, pp. 7729-7742
Closed Access | Times Cited: 12
Targeted therapies in non-small cell lung cancer: present and future
Jessica McLaughlin, Jonathan Berkman, Patrick Nana‐Sinkam
Faculty Reviews (2023) Vol. 12
Open Access | Times Cited: 11
A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments
Fenneke Zwierenga, Bianca van Veggel, Anke van den Berg, et al.
Cancer Treatment Reviews (2023) Vol. 120, pp. 102628-102628
Open Access | Times Cited: 11
Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI
Jianghua Ding, Xingjing Ding, Jiao Zeng, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 4
Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies
Xuejin Ou, Ge Gao, Inbar A. Habaz, et al.
MedComm (2024) Vol. 5, Iss. 9
Open Access | Times Cited: 4
Thérapies moléculaires ciblées en cancérologie pulmonaire
Alice Mogenet, Laurent Greillier, Pascale Tomasini
Encyclopédie médico-chirurgicale. Pneumologie (2025) Vol. 36, Iss. 1, pp. 1-9
Closed Access
Novel strategies for rare oncogenic drivers in non-small-cell lung cancer: An update from the 2024 Annual ESMO meeting
Tijmen J.W.T. van der Wel, Adrianus J. de Langen
Lung Cancer (2025), pp. 108490-108490
Closed Access
Efficacy of EGFR tyrosine kinase inhibitors in patients with non–small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry)
Yuji Uehara, Hiroki Izumi, Ikei S. Kobayashi, et al.
Lung Cancer (2025) Vol. 202, pp. 108479-108479
Open Access
The combination of immune checkpoint inhibitor and chemotherapy may be efficacious for advanced non-small cell lung cancer with near-loop insertions of EGFR exon 20: A retrospective analysis
Kejun Liu, Hongrui Li, Quan-Quan Tan, et al.
Science Progress (2025) Vol. 108, Iss. 1
Open Access
Resistance Mutation Profiles Associated with Current Treatments for Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer in the United States: A Systematic Literature Review
Pratyusha Vadagam, Dexter Waters, Anil Bhagat, et al.
Current Oncology (2025) Vol. 32, Iss. 4, pp. 191-191
Open Access
Page 1 - Next Page

Scroll to top